non-valvular atrial fibrillation (NVAF)
Conditions
Interventions
None listed
Sponsors
The Cardiovascular Institute Academic Organization (CVI ARO)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Consecutive outpatients with 75 years and older receiving apixaban with a diagnosis of non-valvular atrial fibrillation
Exclusion criteria
Exclusion criteria: (1) Apixaban hypersensitivity (2) Clinically significant bleeding (3) River dysfunction with clotting disorder (4) Renal dysfunction (creatinine clearance <15 mL/min) (5) Mitral stenosis and prosthetic valve (6) Inadequate dosage of apixaban at registration (2.5 mg twice a day for those without indications for reducing dose, or 5 mg twice a day for those with them) (7) Patients who did not give written informed consents for this study (8) Venous thromboembolism (deep vein thrombosis and pulmonary thromboembolism) (9) Patients who are judged by the researchers as inadequate for this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Stroke and systemic embolism Bleeding requiring hospitalization | — |
Secondary
| Measure | Time frame |
|---|---|
| Death Cardiovascular death Myocardial infarction Composite endpoints of cardiovascular death, myocardial infarction, stroke, and systemic embolism | — |
Countries
Japan
Contacts
Public ContactKazumi Matsuda
The Cardiovascular Institute Academic Organization (CVI ARO) Head office
Outcome results
None listed